Related Experiment Videos
[Antiviral activity of modified RNAses]
Antibiotiki
|May 1, 1982
Summary
Modifying pancreatic and Act.rimosus RNases with dextran derivatives impacts their antiviral properties. The effectiveness of modified nucleases depends on both the enzyme type and the specific dextran used for modification.
Area of Science:
- Biochemistry
- Virology
- Polymer Chemistry
Background:
- Ribonucleases (RNases) are enzymes with potential antiviral applications.
- Dextran derivatives offer a versatile platform for modifying protein properties.
Purpose of the Study:
- To investigate the antiviral activity of pancreatic RNase and RNase from Act.rimosus after modification with various dextran derivatives.
- To determine how different dextran modifications affect the biological activity of these enzymes against specific viruses.
Main Methods:
- Enzymatic modification of pancreatic RNase and Act.rimosus RNase using different dextran derivatives (e.g., dextran m-aminobenzylhydroxymethyl ether, dialdehyde dextran, dextran hydroxyethylsulfonylanisole ether, dextran sulfate).
- Assessment of the antiviral activity of the modified enzymes against aphthosa and Ayzeku disease viruses.
Main Results:
- Modification with dextran m-aminobenzylhydroxymethyl ether resulted in lower antiviral activity for pancreatic RNase compared to Act.rimosus RNase.
- Dialdehyde dextran modification showed insignificant changes in pancreatic RNase antiviral activity.
- Dextran hydroxyethylsulfonylanisole ether, dextran m-aminobenzylhydroxymethyl ether (with pyridine), and dextran sulfate significantly enhanced the antiviral activity of pancreatic RNase.
Conclusions:
- The antiviral efficacy of modified RNases is highly dependent on the specific enzyme used (pancreatic RNase vs. Act.rimosus RNase).
- The choice of dextran derivative is crucial for achieving enhanced antiviral activity.
- These findings highlight the potential for tailored enzyme-dextran modifications for antiviral therapies.